Valuation: SANA AB

Market Cap 1.82B 186M 163M 152M 140M 262M 17.99B 266M 708M 8.78B 697M 682M 30.44B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 1.82B 186M 163M 152M 140M 262M 17.99B 266M 708M 8.78B 697M 682M 30.44B EV / Sales 2026 *
6.8x
EV / Sales 2027 * 4.68x
Free-Float
81.6%
Yield 2026 *
-
Yield 2027 * -
1 day-0.68%
1 week-0.90%
Current month+0.31%
1 month+1.47%
3 months-7.91%
6 months-47.50%
Current year-37.97%
1 week 12.85
Extreme 12.85
13.5
1 month 12.54
Extreme 12.54
13.83
Current year 12.25
Extreme 12.25
28.3
1 year 8.03
Extreme 8.03
28.3
3 years 1.74
Extreme 1.736
28.3
5 years 1.57
Extreme 1.572
28.3
10 years 1.57
Extreme 1.572
55
Manager TitleAgeSince
Chief Operating Officer 54 2025-02-28
Chief Tech/Sci/R&D Officer 68 2013-12-31
Chief Executive Officer 66 2022-04-29
Director TitleAgeSince
Chairman 71 2022-04-29
Director/Board Member 68 2014-12-31
Director/Board Member 46 2018-01-18
Date Insider Type Main position Quantity % Market Cap.
12/29/25 Sell

Chief Executive Officer

5,000 0.0036%
12/29/25 Sell

Chief Executive Officer

5,000 0.0036%
12/29/25 Sell

Chief Executive Officer

5,000 0.0036%
Change 5-day change 1-year change 3-year change Capi.($)
-0.68%-0.90%+40.34%+43.87% 189M
+1.23%+0.35%+51.62%+87.98% 55.27B
+5.09%+6.24%+63.15%+62.06% 54.15B
+0.25%+0.55%-19.67%-15.22% 23.22B
+0.72%-0.05%+3.84%+409.54% 23.11B
-0.66%+5.35%+30.52%-3.92% 20.33B
-0.37%+0.71%+31.36%-31.61% 17.91B
-0.10%+6.60%+33.70%+549.75% 15.76B
-2.54%-8.73%+164.11%+289.45% 15B
+1.22%-0.05%+22.58%+182.63% 13.82B
Average +0.36%+0.54%+42.16%+157.45% 23.88B
Weighted average by Cap. +1.32%+2.77%+43.55%+134.98%

Financials

2026 *2027 *
Net sales 267M 27.33M 24.03M 22.33M 20.54M 38.51M 2.65B 39.2M 104M 1.29B 103M 100M 4.48B 388M 39.69M 34.91M 32.43M 29.83M 55.94M 3.84B 56.94M 151M 1.87B 149M 146M 6.5B
Net income - -
Net Debt - -
Logo SANA AB
Saniona AB is a Sweden-based company active in the field of biotechnology. It operates in the area of drugs targeting ion channels to develop therapeutics for pain, central nervous system, and inflammatory or autoimmune diseases. The Company develops a technology platform which enables investigation of all types of ion channel drug targets. Its research is focused on GABAA receptors, nicotinic acetylcholine receptors and potassium channels. The clinical pipeline includes: AN788, a clinical candidate for second line treatment of major depressive disorder (MDD); AN761, to be developed for cognition deficits in schizophrenia and Alzheimer's disease; AN363, a candidate for treatment of pain disorders; and AN346, an anti-inflammatory treatment in inflammatory bowel disease (IBD); as well as several other projects. The Company is engaged in partnerships with Janssen Pharmaceuticals Inc, Pfizer Inc and Atlas Venture Inc.
Employees
43
Date Price Change Volume
26-07-23 SEK 13.15 -0.68% 164,092
26-07-22 SEK 13.24 +1.61% 310,266
26-07-21 SEK 13.03 +0.70% 253,062
26-07-20 SEK 12.94 -0.77% 202,188
26-07-17 SEK 13.04 -1.73% 243,260

Net sales - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SANION Stock